23.10.2012 • News

Lonza, OncoMed to Collaborate on Anti-Cancer Therapeutics

Lonza and OncoMed Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced today an agreement for the development and manufacture of OncoMed's pipeline of anti-cancer stem cell therapeutics.

Under the agreement, Lonza will produce material at its mammalian manufacturing facility in Slough, UK. The multi-product GS SystemLicense provides access to Lonza's GS Gene Expression System and Version 8 Media and Feeds Manufacturing Platform.

OncoMed's pipeline is focused on the development of novel monoclonal antibodies that target cancer stem cells.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Top-Feature

most read